The practical guide to online pharmacy advertising compliance in Australia 2025

Online pharmacies move fast. A product range of several thousand SKUs, updated weekly, means marketing copy is being written and published at a pace that has no equivalent in traditional retail. The compliance problem is not unique to pharmacies — it's the same problem every Australian health brand faces — but online pharmacies face it at greater volume and with greater product complexity than almost anyone else.

The regulatory consequence of getting it wrong is significant. The TGA issued 4,806 removal requests in 2023–24 and 147 infringement notices totalling $2.20M. A meaningful proportion of those removal requests targeted digital product content — product pages, category landing pages, and email promotions — published by businesses that believed their copy was compliant. AHPRA assessed 775 advertising complaints in 2024–25, up 104% in two years, with specific enforcement attention on pharmacist-attributed content. The "I didn't realise" defence does not reduce penalties under either framework.

Online pharmacy advertising sits at the intersection of four frameworks that each operate independently.

Therapeutic Goods Act 1989, s.42DL — prohibited advertisements
Section 42DL of the TGA Act creates an absolute prohibition on advertising Schedule 4 (prescription-only) and Schedule 8 (controlled) medicines to the general public. This is not a soft rule with exemptions for online channels — it is a criminal offence. The prohibition extends to product pages, search result snippets, meta descriptions, email subject lines, and any content a consumer can access without a verified prescription. A product page that displays the name, description, or properties of a Schedule 4 medicine in a consumer-facing context is a breach.

Therapeutic Goods Advertising Code 2021 — product claim requirements
The Advertising Code governs how therapeutic goods (including Listed and Registered Medicines) can be advertised. Key requirements for online pharmacy content:

• Claims must not exceed the approved indications on the product's ARTG entry (s.8)
• Mandatory statements must appear in all consumer-directed advertising, including product pages: the AUST L or AUST R number, the sponsor name, and the statement 'Always read the label and follow the directions for use' (ss.14–16)
• Testimonials attributing health outcomes to a therapeutic good are prohibited (s.17)
• Restricted representations — claims relating to serious conditions including cancer, cardiovascular disease, and mental health conditions — require pre-approval from the Secretary (s.20–21)

AHPRA Advertising Guidelines — pharmacist-specific obligations
Where a registered pharmacist is named or featured in advertising, or where the advertising is for a pharmacist's professional services (such as medication reviews, vaccination clinics, or clinical consultations), the AHPRA advertising guidelines apply in addition to TGA rules. Key obligations include the testimonial ban under s.133 of the National Law, and the prohibition on misleading claims about professional services.

Australian Consumer Law — pricing and representations
All online pharmacy pricing and promotional content is subject to the ACL, particularly s.18 (misleading or deceptive conduct) and s.29 (false representations about goods and services). Specific applications include: was/now pricing, bundle offer conditions, PBS co-payment advertising, and any claim about the therapeutic benefits of products that is not substantiated.

The most frequently breached compliance area for online pharmacies is product page copy that exceeds the indications recorded on the product's ARTG entry.

Every Listed Medicine (AUST L) has a set of approved indications in the ARTG. These are the specific health statements the TGA has accepted as appropriate for that product. Marketing copy — product descriptions, feature bullets, category listing copy, and search result snippets — constitutes advertising under the Therapeutic Goods Advertising Code and must remain within these approved indications.

Common product page violations:

Expanded indication claims. An immune support supplement's ARTG entry states "to support immune system health." The product page describes it as "clinically formulated to strengthen your body's natural defences against infection." The second statement exceeds the approved indication and implies disease prevention — a prohibited claim under s.8 of the Advertising Code.

Ingredient-level efficacy claims. A product page lists the ingredients and then attributes specific health outcomes to individual ingredients that are not part of the product's registered indication. For example: "Contains zinc, which reduces the duration and severity of colds." If this claim is not supported by the product's approved indications, it is a breach — even if the underlying evidence about zinc is accurate.

AI-generated copy on ARTG-listed products. Online pharmacies increasingly use AI tools to generate product descriptions at scale. AI-generated copy frequently extrapolates health benefits beyond the product's approved indications, incorporating general ingredient research rather than the specific registered claims. Every AI-generated product page for an ARTG-listed product must be reviewed against the product's ARTG entry before publication.

What product page copy should do:

• Describe the product's uses in language that mirrors or stays within the approved indications
• Include the mandatory AUST L/R number, sponsor name, and 'always read the label' statement
• Avoid testimonials, clinical efficacy comparisons, or implied disease prevention claims
• Link to a full product label or Consumer Medicine Information where available

Category pages on online pharmacy platforms aggregate products by condition, ingredient, or use type. Category-level copy creates a distinct compliance challenge because it makes claims about a product category rather than a specific product — and the advertising framework still applies.

Category descriptions as advertising. Under the Therapeutic Goods Advertising Code, a category page that promotes a range of therapeutic goods to consumers is an advertisement. Claims on that page are held to the same standard as claims on individual product pages. A category page titled "Cold and Flu Relief" with copy stating "fast, effective symptom relief for cold and flu" is making a therapeutic claim on behalf of all products listed on that page. Each of those claims must be substantiated and must not exceed the approved indications of the products in that category.

Prohibited representations in category copy. Category descriptions frequently contain restricted representations — implicit or explicit references to serious conditions that require regulatory pre-approval. Examples include: categories containing language around cardiovascular health ("supports heart health"), mental health ("for stress and anxiety relief"), or weight management ("clinically effective weight loss supplements"). These require review against s.20–21 of the Advertising Code.

PBS and OTC category advertising. Advertising price comparisons, co-payment structures, or PBS availability at the category level requires careful ACL compliance. "PBS medicines available" as a category descriptor is generally permissible. "PBS medicines cheaper here" without substantiation is a potential ACL breach.

The prohibition on advertising Schedule 4 and Schedule 8 medicines to consumers is absolute. For online pharmacies, this means:

• Product pages for prescription medicines may display the product name for the purpose of patient-initiated search and repeat prescription fulfillment — but cannot include promotional copy, health benefit claims, or efficacy descriptions
• Promotional email campaigns cannot include Schedule 4 product names, descriptions, or pricing in consumer-facing communications
• Category pages titled with reference to prescription-only conditions or treatments (e.g. "Erectile Dysfunction Treatments") must be carefully structured so they do not constitute an advertisement for specific Schedule 4 products
• Remarketing campaigns cannot target consumers based on prescription product viewing history with promotional content about those products

The online pharmacy sector's use of condition-based landing pages — where a consumer searches for a condition and lands on a page describing treatment options — creates significant TGA risk if those treatment options include Schedule 4 medicines described in any promotional way.

MISTAKE — Publishing AI-generated product descriptions without ARTG review
PROBLEM — AI tools generate compelling health copy by drawing on general ingredient and category research. For ARTG-listed products, this routinely produces copy that exceeds approved indications or implies unregistered health benefits.
FIX — Implement a mandatory ARTG-check step before any AI-generated product page is published. Cross-reference the generated copy against the product's approved indications in the ARTG.

MISTAKE — Missing mandatory statements on product pages
PROBLEM — Many online pharmacy product pages include health claims, ingredient information, and promotional copy but omit the mandatory AUST number, sponsor name, and 'always read the label' statement required under ss.14–16 of the Advertising Code.
FIX — Implement mandatory statements as a hardcoded template element on all product page layouts for ARTG-listed products.

MISTAKE — Cross-sell and bundle copy implying combined therapeutic effect
PROBLEM — Promotional copy for product bundles often implies a combined or enhanced therapeutic effect from taking multiple products together. For example: "The ultimate winter wellness stack — supercharge your immune defence." This claim about the bundle as a whole may not be supported by the individual products' ARTG entries.
FIX — Bundle and cross-sell copy should be reviewed against the approved indications of each component product individually. Do not extrapolate combined effects.

CompliGUARD reviews online pharmacy marketing content — product page descriptions, category copy, email promotions, and search ad copy — against TGA · AHPRA · FSANZ · ACCC requirements simultaneously. For ARTG-listed products, CompliGUARD cross-references marketing copy against the product's specific approved indications, flagging claims that exceed the registered scope. Every review produces a clause-cited compliance report, a compliant rewrite, and a timestamped record stored in a tamper-evident audit vault. For online pharmacies managing hundreds or thousands of active SKUs, this means product copy can be reviewed at the speed of publication — not days later.

CompliGUARD provides compliance insights based on TGA, FSANZ, ACCC and AHPRA guidance as current at the time of review. The Therapeutic Goods Advertising Code is currently under formal review by the TGA (2025–26). This output does not constitute legal advice.

• Publishing without checking the complete advertisement’s overall impression.
• Treating one regulator’s checklist as coverage for every applicable framework.
• Failing to retain evidence showing what was reviewed and approved before publication.

CompliGUARD reviews the complete advertisement against TGA · AHPRA · FSANZ · ACCC requirements, identifies clause-level risks, proposes compliant wording, and retains the result in an audit trail before publication.